CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 81 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $898,445 | +116.0% | 30,210 | +30.9% | 0.00% | – |
Q2 2023 | $415,992 | -32.4% | 23,085 | -39.8% | 0.00% | – |
Q1 2023 | $615,403 | +14.9% | 38,319 | +31.0% | 0.00% | – |
Q4 2022 | $535,404 | +26.6% | 29,257 | +35.9% | 0.00% | – |
Q3 2022 | $423,000 | -9.2% | 21,521 | -13.8% | 0.00% | – |
Q2 2022 | $466,000 | -19.2% | 24,963 | -5.1% | 0.00% | – |
Q1 2022 | $577,000 | -30.6% | 26,293 | -10.2% | 0.00% | – |
Q4 2021 | $832,000 | -56.1% | 29,271 | -67.5% | 0.00% | -100.0% |
Q3 2021 | $1,896,000 | +12.9% | 90,056 | +1.1% | 0.00% | 0.0% |
Q2 2021 | $1,679,000 | +29.4% | 89,086 | +4.8% | 0.00% | 0.0% |
Q1 2021 | $1,298,000 | +349.1% | 84,966 | +315.1% | 0.00% | – |
Q4 2020 | $289,000 | +19.4% | 20,471 | +32.7% | 0.00% | – |
Q3 2020 | $242,000 | -2.0% | 15,427 | +9.2% | 0.00% | – |
Q2 2020 | $247,000 | +341.1% | 14,121 | +271.8% | 0.00% | – |
Q1 2020 | $56,000 | -44.0% | 3,798 | -5.5% | 0.00% | – |
Q4 2019 | $100,000 | +122.2% | 4,020 | +29.6% | 0.00% | – |
Q3 2019 | $45,000 | -44.4% | 3,101 | -5.4% | 0.00% | – |
Q2 2019 | $81,000 | -61.4% | 3,278 | -64.9% | 0.00% | – |
Q1 2019 | $210,000 | +3.4% | 9,346 | +36.5% | 0.00% | – |
Q4 2018 | $203,000 | -76.1% | 6,846 | -76.9% | 0.00% | – |
Q3 2018 | $848,000 | – | 29,683 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |